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emporal arteritis and polymyalgia rheumatica, different T clinical manifestations of the same systemic granuloma- 
tous vasculitis, predominantly affect older persons.' Huston 
and colleagues estimated the prevalence to be 1 in 750 per- 
sons older than 50 years of age.' Temporal arteritis often 
requires high and sometimes sustained corticosteroid therapy 
to prevent the development of sight threatening complica- 
tions.'-' Often, corticosteroids alone are used for the entire 
length of the treatment course, which may exceed 1 year. This 
is in contrast to other collagen vascular diseases/vasculitides, 
in which other steroid-sparing immunosuppressive agents are 
used in combination to reduce the dose of corticosteroids.8 
Corticosteroids exert their immunosuppressive effect 
principally on cell-mediated immunity.' This arm of the 
immune system is particularly important for defense against a 
variety of different intracellular pathogens. Thus, patients 
receiving corticosteroid therapy are at  increased risk of infec- 
tion caused by intracellular organisms. Although intracellu- 
lar pathogens are frequently thought of in the differential 
diagnosis of pneumonia and sepsis syndrome in patients with 
hematological malignancies or transplants, these types of 
pathogens are rarely considered in the differential diagnosis 
of patients with temporal arteritis. We report the cases of 
three patients who received corticosteroids for temporal ar- 
teritis and who subsequently were infected with opportunis- 
tic pathogens. In all three, the opportunistic infection was not 
considered with the initial diagnosis. 
CASE REPORTS 
Case 1 
A 77-year-old man was diagnosed as having temporal 
arteritis in October 1994. He was treated with 60 mg pred- 
nisone daily and showed improvement in his symptoms of 
headache and muscle weakness. His prednisone dosage was 
reduced to 40 mg by January 1995. In February 1995, he was 
admitted to hospital for the treatment of pneumonia. Chest 
roentgenogram revealed bibasilar patchy infiltrates. Treat- 
ment with ceftriaxone and erythromycin followed by amoxi- 
cillinklavulanic acid and clarithromycin failed to clear the 
chest roentgenogram findings. He had several subsequent 
hospitalizations over the next 3 months for the treatment of 
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Clostridium dificile colitis, funguria, and a Pseudomonas 
aeruginosa and enterococcal urinary tract infection. 
In July 1995, the patient was admitted to hospital with 
dyspnea, difficulty walking, and vomiting. He was taking 25 
mg prednisone daily. On examination, he had a temperature 
of 985°F (37.1°C), and respirations were 28/min. He was 
alert but distractable and had no signs of meningismus. 
Neurological exam revealed intact cranial nerve function and 
normal peripheral power and sensation with symmetrical 
reflexes. The hemoglobin was 12.4 g/dL, white blood cell 
count was 1 6,900/mm3, platelets were 25,000/mm3. Chest 
roentgenogram revealed persistent bilateral, patchy infil- 
trates, predominantly affecting the lower lobes (Figure 1). 
Bronchoscopy was performed, and transbronchial bi- 
opsy revealed chronic inflammation and budding yeasts. Cul- 
ture of bronchoalveolar fluid yielded Cryptococcus neofor- 
mans. Cerebrospinal fluid microscopy showed budding 
yeasts, cryptococcal antigen was positive at  a titer of 1:2048, 
and culture was positive for C. neoformans. Urine culture 
was positive for C. neoformans, but serum cryptococcal 
antigen titer was negative. The patient was treated with 6 
weeks of amphotericin B (0.4 mg/kg/d) plus flucytosine (ad- 
justed for renal function). After completion of this therapy, 
fluconazole 50 mg daily (adjusted for creatinine of 2.3 mg/ 
dL) was begun. Although his pulmonary and mental status 
improved on this regimen, he died at  home 4 weeks after 
discharge, and autopsy was not obtained. 
Case 2 
A 71-year-old man was diagnosed with temporal arteri- 
tis in August 1995. He was prescribed a dosage of 60 mg of 
Prednisone daily, with improvement of diplopia and visual 
loss. In October 1995, he was admitted to hospital with 
cellulitis of his right lower extremity and a malleolar ulcer 
attributable to peripheral vascular disease. Following intra- 
venous antibiotics and debridement, he was admitted to the 
Geriatric Evaluation and Management service for rehabilita- 
tion. 
In November 1995, while on a daily dosage of 40 mg 
prednisone, the patient became dyspneic, with rigors and a 
fever of 100.4"F (38°C). White blood cell count was 9600/ 
mmY3 (86% neutrophils), and hemoglobin was 15.4 g/dL. A 
chest roentgenogram revealed diffuse bilateral infiltrates (Fig- 
ure 2). Ampicillin/sulbactam, 1.5 g every 8 hours, was begun. 
His condition deteriorated and he was transferred to the 
intensive care unit where arterial blood gases showed pH 7.5, 
PaOz 61 mm Hg, PaC02 28 mm Hg on 100% O2 face mask. 
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Figure 1. Chest roentgenogram showing bilateral patchy infil- 
trates attributable to Cryptococcus neoformans (Case 1). 
The following day he underwent bronchoscopy. Cytological 
examination of the bronchoalveolar fluid revealed many 
Pneumocystis carinii organisms. Despite treatment with in- 
travenous trimethopridsulphamethoxazole therapy (15 mg/ 
Wd), the patient’s condition did not improve. His course was 
complicated by a myocardial infarction, the development of 
acute renal failure, P .  aeruginosa pneumonia, and an upper 
gastrointestinal bleed. He died 17 days after admission to the 
intensive care unit. 
Case 3 
A-74-year old man was admitted in August 1995 for the 
treatment of a urinary tract infection caused by Serratia 
marcescens and osteomyelitis underlying a malleolar ulcer. 
His medical history was significant for insulin-requiring dia- 
betes mellitus with nephropathy, hypothyroidism, and hyper- 
tension. In October 1995, he complained of blurred vision 
and jaw claudication, and examination revealed left temporal 
artery tenderness. A presumptive diagnosis of temporal ar- 
teritis was made, based on his clinical picture and a temporal 
artery biopsy, which was suggestive, but not diagnostic, of 
temporal arteritis. His symptoms responded well to pred- 
nisone 60 mg daily, and 14 days into corticosteroid therapy, 
the Westergren sedimentation rate had fallen from 110 to 25 
m d h .  Prednisone was gradually tapered such that he was 
receiving 40 mg daily by November 1995. On Novmber 27, 
1995, he developed stupor, dyspnea, and a temperature of 
101°F (38.3”C). Despite the correction of his blood glucose of 
24 mg/dL to normal, his somnolence did not improve. His 
hemoglobin was 13.5 g/dL, white blood cell count was 
1 8,900/mm3,and platelets were 126,000/mm.3 Arterial blood 
gases showed a pH of 7.5, PaO, 49 mmHg, PaC02 38.5 
mmHg and bicarbonate of 30 mmol/L on room air. A chest 
Figure 2. Chest roentgenogram showing diffuse interstitial dis- 
ease with patchy infiltrates attributable to Pneumocystis carinii 
(Case 2 ) .  
roentgenogram showed left perihilar air space disease, and 
sputum sample revealed >25 white blood cells per high 
powered field, moderate Gram positive bacilli, and few Gram 
positive cocci; culture yielded only normal flora. Four blood 
culture bottles yielded Listeria moncytogenes. He responded 
well to ampicillin, 2 g intravenously every 4 hours, for 21 
days and was discharged to home on prednisone 20 mg/d in 
January 1996. 
DISCUSSION 
These three cases illustrate that patients in whom tem- 
poral arteritis is treated with corticosteroids are at  increased 
risk of infection with opportunistic pathogens such as P .  
carinii, L. monocytogenes, and C. neoformans. Increasingly, 
there is recognition that these organisms are widely distrib- 
uted in the environment and can be acquired easily. However, 
disease occurs almost entirely in patients who are immuno- 
compromised. 
Various reports have suggested that mortality in patients 
with temporal arteritis is increased compared with the nor- 
ma1 age-matched p ~ p u l a t i o n . ~ - ~ ~ ~ ’  Other authors have not 
shown such an increase in mortality.”-7 However, if mortality 
is increased, it is unclear if such an increase is related to the 
disease itself or complications of its treatment. Longitudinal 
cohort studies which contain small numbers of patients do 
not show statistically significant increases in infection rates 
for patients who have temporal arteritis and who are treated 
with corticosteroids, when compared with the normal popu- 
lati~n.,’”’~ Anecdotal reports of opportunistic infections re- 
ported in temporal arteritis have included invasive aspergil- 
l o s i ~ , ’ ~ , ~ ~  nocardiasis,” t u b e r ~ u l o s i s , ~ ” ~  varicella-zoster 
i n f e ~ t i o n ’ ~  and pneumocystis pneumonia.20,21 
P .  carinii pneumonia (PCP) has become increasingly 
important with the epidemic of acquired immune deficiency 
syndrome (AIDS).22 However, this organism is a recognized 
complication of many other immunodeficiency states, includ- 
ing immunoglobulin deficiencies, malnutrition, hematologi- 
cal malignancies, and t ransplan ta t i~n .~~-~’  Moreover, with 
the advent of significant immunosuppressive regimens for 
many rheumatological and dermatological disorders, the in- 
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cidence of PCP in patients with these diseases has increased in 
recent years.29 
Crayton and Sundstrom reported a case of PCP occur- 
ring in a 71-year-old man who had temporal arteritis and 
who had received corticosteroids for 5 weeks.20 In a retro- 
spective review of all non-AIDS-associated episodes of PCP 
diagnosed at the Mayo Clinic between 1985 and 1991, Yale 
and Limper described five cases of PCP in patients with 
temporal arteritk21 Other retrospective reviews of PCP do 
not re ort PCP occurring in patients with temporal arteri- 
t i~~~-”al though patients with other collagen vascular disor- 
ders, such as Wegener’s granulomatosus, systemic lupus ery- 
thematosus, dermatomyositis, and rheumatoid arthritis have 
been reported with PCP.27,28 
Prophylaxis against PCP has become standard treatment 
for patients with AIDS and acute leukemia and following 
transplantation. However, prophylaxis is not recommended 
routinely for patients undergoing treatment of connective 
tissuekollagen vascular disorders, inflammatory bowel dis- 
ease, or dermatological conditions. Sepkowitz et al. have 
suggested that reasons for changes in the spectrum of under- 
lying disorders seen in patients with PCP over time, in part, 
reflect this changing use of pro phyla xi^.^' There is still no 
concensus regarding the use of prophylaxis against PCP with 
trimethoprindsulphamethoxazole in patients with temporal 
arteritis treated with corticosteroids. Because the numbers of 
infections in patients with temporal arteritis caused by P. 
carinii is small, the risk of side effects from the trimethoprid 
sulphamethoxazole may outweigh the benefits obtained by 
routine use of the drug. 
L. monocytogenes has been reported rarely as a compli- 
cation of temporal arteritis. Pigrau et al. noted in a brief 
communication that five of 51 adults with listeriosis had 
“systemic lupus erythematosus or Horton’s (temporal) arteri- 
tis,” but no specific patient data were reported.31 This lack of 
cases is perhaps surprising given the incidence of listeriosis 
throughout the world. Skogberg, et al. described 74 patients 
with Listeria infection in Finland; five of these patients had 
collagen vascular disorders.” Kraus et al. described eight 
patients who had collagen vascular diseases other than tem- 
poral arteritis and who developed l i s te r io~is .~~ Of 57 adults 
with listeriosis in an outbreak associated with soft cheese 
ingestion in Switzerland, none had vas~u l i t i s .~~  Although not 
specifically reported, it seems likely that any patient with 
listeriosis complicating temporal arteritis could have been 
grouped with “collagen vascular disorders” in previous se- 
ries. 
There is clearly an increased risk of listeriosis with in- 
creasing age.12 The Centers for Disease Control and Preven- 
tion have estimated that sporadic cases of Listeria infection 
occur in the United States at a rate of 7.1 per lo6 population 
per year.12 Excluding pregnancy-associated cases, the inci- 
dence is lowest and relatively constant during the first 4 
decades of life and increases thereafter. By age 70, the inci- 
dence is 21 cases per lo6 population. Although this increase 
in incidence may be explained by a waning immune system in 
older people, it is just as likely that decreasing gastric acidity 
allows a larger inoculum of this food-borne athogen to pass 
through the stomach and cause d i ~ e a s e . ~ ~ , ~ .  
C. neoformans is an encapsulated yeast that most com- 
monly causes chronic meningitis. 14,36 It appears that intact 
cell-mediated immune systems are important host defenses 
against this organism. The incidence of cryptococcosis has 
P 
increased with the AIDS epidemi~’~; in non-HIV-infected 
people, common underlying diseases include lymphoma, leu- 
kemia, and tran~plantation.’~~~~~~~ Ho wever, in the non-HIV 
population, up to 50% may have no known associated im- 
munosuppressive disease. l3 Schimpff and Bennett showed 
subtle in vitro abnormalities of cell-mediated immunity in six 
apparently normal individuals with cryptococcal disease and 
suggested that these defects might explain the susceptibility 
to this fungus.38 
The older adult may present with atypical manifestations 
of meningitis; there are anecdotal reports of cryptococcal 
meningitis presenting as dementia or new onset confusion in 
the older a d ~ l t . ~ ~ . ~ ’  We believe that there are no reports of 
cryptococcal disease complicating temporal arteritis al- 
though corticosteroid therapy in sarcoidosis and systemic 
lupus erythematosus has been associated with cryptococco- 
sis. 14,3637 
Most probably, our patients were at risk for opportunis- 
tic infections for at least three possible reasons. It is likely that 
the most important of these risk factors was the use of 
corticosteroids. Corticosteroids have been shown to increase 
the risk of infection in both animals and  human^.^^,^^ Re- 
cently, Stuck et al. examined the association between corti- 
costeroid therapy and subsequent infection using a meta- 
analysis of 71 controlled clinical trials in which patients were 
randomized to treatment with or without cortico~teroids.~~ 
The relative risk of infection was 1.6 (confidence interval 
0.9-2.3) in patients receiving corticosteroids but was greater 
in those with underlying neurological disease. This effect was 
cumulative and dose-dependent. No increased rate was seen 
in those receiving < lo  mg daily or <700 mg total. At the 
cellular level, corticosteroid therapy inhibits T-lymphocyte 
function and IL-2 production and suppresses monocyte func- 
tion and production.’ 
The use of corticosteroids has been shown to contribute 
to the risk of infection with P.  carinii and C. neoformans in 
both animals and humans.10~13i44 Successful infection of rats 
with P .  carinii requires the animals to be treated with corti- 
costeroids in order to produce pneumonia.” Experimental 
animal studies have shown a decrease in the size of the 
inoculum required to induce L. monocytogenes infection in 
steroid-treated rats when compared with rats not treated 
with cort ic~steroids .~~ 
Secondly, our patients were all more than 65 years of 
age. Aging has been shown to decrease cell-mediated immu- 
nity in both animal models and  human^.^^-^' Older people 
have been shown to be at increased risk for many a ents 
Age alone is thought to be a sufficient predisposing factor for 
acquisition of these diseases. No such clearly defined age risk 
exists for PCP, but interestingly, Jacobs et al. described a 
cluster of five immunocompetent patients, who were all more 
than 65 years old and who were diagnosed with PCP.’l 
Thirdly, the presence of temporal arteritis may have 
contributed to a dysregulation of the immune system with 
concomitant increased susceptibility to infection. Certainly, 
macrophage and T cell activation, thought to be related to the 
disease itself has been found in patients with temporal arteri- 
t k S 2  However, temporal arteritis is a disease which rarely 
affects those less than 50 years old and in whom high dose 
corticosteroid therapy is the standard treatment regimen. 
Thus, ability to dissect the relative contribution to infection 
from temporal arteritis, therapy, and age is difficult. 
including listeriosis, cryptococcosis, and tuberculosis. ,g49,5; 
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Patients with temporal arteritis often have dramatic 
symptomatic improvement with corticosteroid therapy. High 
doses are required to initially control symptoms, and relapses 
may occur if corticosteroids are tapered too quickly. Patients 
with temporal arteritis are commonly more than 50 years old 
and are exposed to long courses of corticosteroids with all 
their attendant complications in older people, including dia- 
betes mellitus, altered mentation, and osteoporosis. The pa- 
tient with temporal arteritis is, therefore, at risk from infec- 
tions that which may be uncommon otherwise, and we 
should remain cognizant of this possibility. Diagnoses of 
possible opportunistic infections should be actively pursued 
to ensure such patients are given appropriate therapy. 
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